Supportive therapy

The general treatment of respiratory disease and right heart failure are essential to the management of PAH patients.


It is recommended

  • To introduce diuretic treatment in PAH patients with signs of right ventricular failure and fluid retention [I, C].
  • To introduce continuous long-term O therapy in PAH patients when arterial blood O pressure is consistently less than 8 kPa (60 mmHg) [I, C].
  • To consider oral anticoagulant treatment in patients with IPAH (group 1.1), heritable PAH (group 1.2), and PAH due to use of anorexigens (group 1.3) [IIa, C]. Oral anticoagulant treatment may be considered in patients with PAH associated with diseases of group 1.4. [IIb, C]. Hemorrhagic risk must be carefully evaluated, especially for patients with porto-pulmonary hypertension (group 1.4.2).
  • To consider use of digoxin in PAH patients who develop atrial tachyarrhythmia [IIb, C].

 

Suche
Hier erfahren Sie mehr über Patientenorganisationen...

 mehr

SSPH Research Prize 2012
Deadline for submission: April 30, 2012

Further information


Symposium "pulmonal-arterielle Hypertension im Kindesalter"
Donnerstag, 10. Mai 2012, 16.00-18.00, Bern

Further information:


5th International Congress of the Swiss Society of Pulmonary Hypertension (SSPH)
28.-29. September 2012, Thun, Congress Hotel Seepark Thun

Informationen: www.imk.ch/sgph2012




 mehr